We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Soothing Music Reduces Awareness of Tinnitus Buzz

By HospiMedica International staff writers
Posted on 14 Jan 2009
An innovative audio device promises to treat tinnitus (ringing in the ears) by promoting desensitization of tinnitus perception, thus reducing consciousness of the disturbing sounds.

The Oasis is a compact, noninvasive medical device that delivers customized music embedded with a pleasant acoustic neural stimulus, designed to complement each patient's individual audiologic profile. More...
The signal stimulates the auditory pathways to promote neural plastic changes; over time, these changes help the brain filter out the tinnitus associated sounds from conscious attention and reduce the associated tinnitus disturbance, providing long-term relief from symptoms. After clinical customization, the patient listens to the device daily for at least six months; for the first two months, the music mix includes a noise, which some describe as water in a shower, to cover the tinnitus. In the third month, the shower sound is removed and patients are instructed to turn up the music just loud enough so the tinnitus is audible only during the quiet parts. After six months, patients use the device as needed. In this way, the therapy can help the brain filter out the tinnitus perception, so that it no longer intrudes on the patient's conscious attention, and no longer has a disturbing impact on quality of life. The device provides stimulation across a broad frequency range (100 Hz-12.5 KHz) and allows interaction with tinnitus perception, at comfortable listening levels, of up to 80 decibels through high quality earphones. The Oasis is a product of Neuromonics (Bethlehem, PA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

A recent cohort study to evaluate the device involved the first 470 patients to undertake the treatment in seven Neuromonics tinnitus clinics. Tinnitus disturbance was assessed before, during, and after treatment with the Tinnitus Reaction Questionnaire. The results showed that among the most suitable patients, 92% exceeded the threshold for success (defined as a reduction in tinnitus-related disturbance of at least 40%), and the mean improvement in tinnitus disturbance was 72%; the discontinuance rate was 4%. For other suitability categories, the success rates and mean improvements were somewhat lower, and the discontinuance rates higher. The study was published in the November 2008 issue of Annals of Otololgy, Rhinology and Laryngology.

"By comprehensively addressing tinnitus' underlying neurological processes, Neuromonics is uniquely positioned to help the millions of patients seeking quality-of-life improvements,” said study coauthor Peter Hanley, Ph.D., of Neromonics. "Neuromonics Tinnitus Treatment leads to significant improvements for a broad cross-section of patients with tinnitus.”

Tinnitus can be perceived in one or both ears or in the head. It is usually described as a ringing noise, but in some patients it takes the form of a high pitched whining, buzzing, hissing, humming, or whistling sound, or as ticking, clicking, or roaring. Tinnitus can have many different causes, but most commonly results from otologic disorders, such as exposure to excessive or loud noises, or ototoxic drugs, that can cause tinnitus with or without hearing loss. However, tinnitus, just as sudden onset hearing loss, may also have no obvious external cause.

Related Links:

Neuromonics 



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.